AVTR · available-data snapshot
Avantor, Inc. (AVTR): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Avantor, Inc. (AVTR); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for AVTR?
We do not publish a fair value for Avantor, Inc.. What we can say from its filings and market data is below.
What is AVTR's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: growth is slow or negative.
- Value · 71 of 100
Cheaper than 71% of Healthcare companies in US
- Price vs worth · 54 of 100
- Quality · 28 of 100
More profitable than 28% of Healthcare companies in US
- Financial health · 28 of 100
Financially stronger than 28% of Healthcare companies in US
- Growth · 17 of 100
Growing faster than 17% of Healthcare companies in US
- Momentum · 81 of 100
Outperformed 81% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $16.27
- Market cap
- $11,
000, 976, 384 - 52-week high
- $16.55
- 52-week low
- $7.26
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Avantor, Inc. (AVTR) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, AVTR trades at a recent price of $16.27, a market capitalisation of about $11,000,976,384, sitting 97% of the way up its 52-week range ($7.26–$16.55), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing AVTR's trading multiples against a sector benchmark. Here that gives Fwd P/E of 18.5× (in line with the peer median of 17.5×); P/B of 2.0× (cheaper than the peer median of 7.8×); P/S of 1.7× (cheaper than the peer median of 6.2×); EV/EBITDA of 15.4× (cheaper than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. AVTR shows a price-to-book (P/B) of 1.95 and book value of $8.32 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. AVTR is in an up-trend (price above both its 50- and 200-day averages), trading -1.7% from its 52-week high. Over the past year the stock is +8.2%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
AVTR vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | AVTR | Peer median | Read |
|---|---|---|---|
| Fwd P/E | 18.5× | 17.5× | in line with |
| P/B | 2.0× | 7.8× | cheaper than |
| P/S | 1.7× | 6.2× | cheaper than |
| EV/EBITDA | 15.4× | 18.5× | cheaper than |
What does Avantor, Inc. do?
What does it do?
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in United States. The company employs roughly 13,500 people.
How does it make money?
The business turns $6.6B in annual revenue into profit. Out of every $100 of sales, about $7 is left as operating profit (operating margin of 7.2%), after a 32% gross margin on the products/services it sells. After all costs, taxes and interest, -8.8% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.7× equity), comfortably covers its short-term bills (1.8× current ratio), and is currently lossmaking.
Who at AVTR filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Garner Todd W | EVP and CFO | Grant / award | — | Form 4 for Garner Todd W (opens sec.gov in a new tab) | |
| Ligner Emmanuel | Director, President and CEO | Shares withheld (tax) | $397,273.99 | Form 4 for Ligner Emmanuel (opens sec.gov in a new tab) | |
| Hankamer Brittany | EVP, Chief HR Officer | Shares withheld (tax) | $2,472.46 | Form 4 for Hankamer Brittany (opens sec.gov in a new tab) | |
| Eck Steven W | SVP & Chief Accounting Officer | Shares withheld (tax) | $19,085.30 | Form 4 for Eck Steven W (opens sec.gov in a new tab) | |
| Sokenu Claudius | EVP, Chief Legal & Compliance | Shares withheld (tax) | $13,739.44 | Form 4 for Sokenu Claudius (opens sec.gov in a new tab) | |
| Walker Corey | President, VWR Dist. & Servs. | Shares withheld (tax) | $28,835.80 | Form 4 for Walker Corey (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.